Report

  1. Home
  2. Discounted reports

Cancer Monoclonal Antibodies Market By Antibody Type (Murine, Chimeric, Humanized), By Application (Blood Cancer, Breast Cancer, Lung Cancer, Others), By End User (Hospitals and Clinics, Research and Academic Institute/Laboratories): Global Opportunity Analysis and Industry Forecast, 2021-2031

Market Report I 2023-02-01 I 300 Pages I Allied Market Research
Discounted by 10% to 2024-11-15

The global cancer monoclonal antibody testing market size was $55,640.00 million in 2021 and is predicted to grow with a CAGR of 7.0%, by generating a revenue of $106,825.10 million by 2031.
Monoclonal antibodies are synthetic antibodies that are directed against specific sites in the human body. On the surface of the cancer-causing cells, they serve as antigens. There are numerous monoclonal antibodies, and each one is made to solely attach to one kind of antigen. These antibodies are frequently used to treat a number of illnesses, including some forms of cancer. They deliver radioactive materials or injectable medications directly to the cancer cells. According to a study, radioactive cancer therapy is the most often used type of cancer therapy worldwide.
The increase in the geriatric population, rise in the incidence of cancer, and increase in demand for novel vaccines and therapies are some of the primary factors anticipated to drive the cancer monoclonal antibody testing market growth. The demand for effective therapies has increased owing to the rise in prevalence of different types of cancer like lung cancer, around the world, prompting researchers and scientists to accelerate their research efforts and produce effective monoclonal drugs for cancer.These factors are projected to drive the market growth during the forecast period.
The market is significantly constrained by the high costs associated with the creation of monoclonal antibodies using cutting-edge technology. The complicated manufacturing procedure, pricey biological and chemical components, clinical trials, as well as necessary efficacy, safety, and quality tests, are the main causes of the high cost of cancer monoclonal antibody testing. Large-scale synthesis of monoclonal antibodies involving manydisulfidebonds and post-translational modifications necessitates the use of expensive, specialized equipment. All these are the major factors projected to hamper the market growth during the forecast period.
Governments of various countries around the world are investing in the development of advanced cancer diagnosis and treatment methods, which is expected to boost the growth of the cancer monoclonal antibody testing market. Furthermore, many countries have established programs and initiatives aimed at providing access to cancer care for their citizens, further driving the demand for cancer monoclonal antibody tests. The increase in government support is also driving the development of new cancer monoclonal antibody tests, which are more accurate, reliable, and cost-effective. This is leading to a rise in the number of cancer patients being diagnosed at an early stage, which is increasing the demand for cancer monoclonal antibody tests. This contributes to the market rise in the cancer monoclonal antibody testing market.
The COVID-19 pandemic has had a negative impact on the cancer monoclonal antibody testing industry. During the initial phase of the pandemic, the coronavirus 2019 (COVID-19), caused significant challenges in the supply of materials, production, and logistical operations, and significantly impacted research and drug development activities. When the COVID-19 pandemic began, most businesses and research initiatives around the world suspended operations, reducing market demand for reagents and other laboratory equipment.
The key players profiled in this report include F. Hoffmann-La Roche Ltd., Bristol Myers, Squibb Co., Merck & Co., GlaxoSmithKline plc, Johnson & Johnson, Amgen, Inc., Novartis AG, AstraZeneca plc, Eli Lilly and Company, and AbbVie.
Key Benefits For Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cancer monoclonal antibodies market analysis from 2021 to 2031 to identify the prevailing cancer monoclonal antibodies market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the cancer monoclonal antibodies market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global cancer monoclonal antibodies market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By End User
- Hospitals and Clinics
- Research and Academic Institute/Laboratories
By Antibody Type
- Murine
- Chimeric
- Humanized
By Application
- Blood Cancer
- Breast Cancer
- Lung Cancer
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- UAE
- South Africa
- Rest of LAMEA
- Key Market Players
- Roche Holdings Ltd
- Johnson & Johnson
- Pfizer Inc.
- Novartis AG
- AstraZeneca plc
- Merck & Co. Inc.
- Celgene Limited
- Bistrol-Myers Squibb
- Eli Lilly & Co.
- Abbvie Inc

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
3.6. Key Regulation Analysis
3.7. Market Share Analysis
3.8. Patent Landscape
3.9. Regulatory Guidelines
3.10. Value Chain Analysis
CHAPTER 4: CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Murine
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Chimeric
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Humanized
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Blood Cancer
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Breast Cancer
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Lung Cancer
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Others
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals and Clinics
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Research and Academic Institute/Laboratories
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
CHAPTER 7: CANCER MONOCLONAL ANTIBODIES MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Antibody Type
7.2.3. Market size and forecast, by Application
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Antibody Type
7.2.5.1.3. Market size and forecast, by Application
7.2.5.1.4. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Antibody Type
7.2.5.2.3. Market size and forecast, by Application
7.2.5.2.4. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Antibody Type
7.2.5.3.3. Market size and forecast, by Application
7.2.5.3.4. Market size and forecast, by End User
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Antibody Type
7.3.3. Market size and forecast, by Application
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Antibody Type
7.3.5.1.3. Market size and forecast, by Application
7.3.5.1.4. Market size and forecast, by End User
7.3.5.2. UK
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Antibody Type
7.3.5.2.3. Market size and forecast, by Application
7.3.5.2.4. Market size and forecast, by End User
7.3.5.3. France
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Antibody Type
7.3.5.3.3. Market size and forecast, by Application
7.3.5.3.4. Market size and forecast, by End User
7.3.5.4. Spain
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Antibody Type
7.3.5.4.3. Market size and forecast, by Application
7.3.5.4.4. Market size and forecast, by End User
7.3.5.5. Italy
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Antibody Type
7.3.5.5.3. Market size and forecast, by Application
7.3.5.5.4. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Antibody Type
7.3.5.6.3. Market size and forecast, by Application
7.3.5.6.4. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Antibody Type
7.4.3. Market size and forecast, by Application
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. China
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Antibody Type
7.4.5.1.3. Market size and forecast, by Application
7.4.5.1.4. Market size and forecast, by End User
7.4.5.2. Japan
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Antibody Type
7.4.5.2.3. Market size and forecast, by Application
7.4.5.2.4. Market size and forecast, by End User
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Antibody Type
7.4.5.3.3. Market size and forecast, by Application
7.4.5.3.4. Market size and forecast, by End User
7.4.5.4. South Korea
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Antibody Type
7.4.5.4.3. Market size and forecast, by Application
7.4.5.4.4. Market size and forecast, by End User
7.4.5.5. Australia
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Antibody Type
7.4.5.5.3. Market size and forecast, by Application
7.4.5.5.4. Market size and forecast, by End User
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Antibody Type
7.4.5.6.3. Market size and forecast, by Application
7.4.5.6.4. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Antibody Type
7.5.3. Market size and forecast, by Application
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Antibody Type
7.5.5.1.3. Market size and forecast, by Application
7.5.5.1.4. Market size and forecast, by End User
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Antibody Type
7.5.5.2.3. Market size and forecast, by Application
7.5.5.2.4. Market size and forecast, by End User
7.5.5.3. UAE
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Antibody Type
7.5.5.3.3. Market size and forecast, by Application
7.5.5.3.4. Market size and forecast, by End User
7.5.5.4. South Africa
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Antibody Type
7.5.5.4.3. Market size and forecast, by Application
7.5.5.4.4. Market size and forecast, by End User
7.5.5.5. Rest of LAMEA
7.5.5.5.1. Key market trends, growth factors and opportunities
7.5.5.5.2. Market size and forecast, by Antibody Type
7.5.5.5.3. Market size and forecast, by Application
7.5.5.5.4. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1. Roche Holdings Ltd
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.2. Johnson & Johnson
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.3. Pfizer Inc.
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.4. Novartis AG
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.5. AstraZeneca plc
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.6. Merck & Co. Inc.
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.7. Celgene Limited
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.8. Bistrol-Myers Squibb
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.9. Eli Lilly & Co.
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.10. Abbvie Inc
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot

LIST OF TABLES
TABLE 01. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 02. CANCER MONOCLONAL ANTIBODIES MARKET FOR MURINE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 03. CANCER MONOCLONAL ANTIBODIES MARKET FOR CHIMERIC, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 04. CANCER MONOCLONAL ANTIBODIES MARKET FOR HUMANIZED, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 05. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 06. CANCER MONOCLONAL ANTIBODIES MARKET FOR BLOOD CANCER, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 07. CANCER MONOCLONAL ANTIBODIES MARKET FOR BREAST CANCER, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 08. CANCER MONOCLONAL ANTIBODIES MARKET FOR LUNG CANCER, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 09. CANCER MONOCLONAL ANTIBODIES MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 10. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 11. CANCER MONOCLONAL ANTIBODIES MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 12. CANCER MONOCLONAL ANTIBODIES MARKET FOR RESEARCH AND ACADEMIC INSTITUTE/LABORATORIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 13. CANCER MONOCLONAL ANTIBODIES MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 14. NORTH AMERICA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 15. NORTH AMERICA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 16. NORTH AMERICA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 17. NORTH AMERICA CANCER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 18. U.S. CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 19. U.S. CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 20. U.S. CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 21. CANADA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 22. CANADA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 23. CANADA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 24. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 25. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 26. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 27. EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 28. EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 29. EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 30. EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 31. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 32. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 33. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 34. UK CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 35. UK CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 36. UK CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 37. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 38. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 39. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 40. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 41. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 42. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 43. ITALY CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 44. ITALY CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 45. ITALY CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 46. REST OF EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 47. REST OF EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 48. REST OF EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 49. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 50. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 51. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 52. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 53. CHINA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 54. CHINA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 55. CHINA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 56. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 57. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 58. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 59. INDIA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 60. INDIA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 61. INDIA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 62. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 63. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 64. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 65. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 66. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 67. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 68. REST OF ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 69. REST OF ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 70. REST OF ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 71. LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 72. LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 73. LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 74. LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 75. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 76. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 77. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 78. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 79. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 80. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 81. UAE CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 82. UAE CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 83. UAE CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 84. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 85. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 86. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 87. REST OF LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 88. REST OF LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 89. REST OF LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 90. ROCHE HOLDINGS LTD: KEY EXECUTIVES
TABLE 91. ROCHE HOLDINGS LTD: COMPANY SNAPSHOT
TABLE 92. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 93. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 94. PFIZER INC.: KEY EXECUTIVES
TABLE 95. PFIZER INC.: COMPANY SNAPSHOT
TABLE 96. NOVARTIS AG: KEY EXECUTIVES
TABLE 97. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 98. ASTRAZENECA PLC: KEY EXECUTIVES
TABLE 99. ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 100. MERCK & CO. INC.: KEY EXECUTIVES
TABLE 101. MERCK & CO. INC.: COMPANY SNAPSHOT
TABLE 102. CELGENE LIMITED: KEY EXECUTIVES
TABLE 103. CELGENE LIMITED: COMPANY SNAPSHOT
TABLE 104. BISTROL-MYERS SQUIBB: KEY EXECUTIVES
TABLE 105. BISTROL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 106. ELI LILLY & CO.: KEY EXECUTIVES
TABLE 107. ELI LILLY & CO.: COMPANY SNAPSHOT
TABLE 108. ABBVIE INC: KEY EXECUTIVES
TABLE 109. ABBVIE INC: COMPANY SNAPSHOT

LIST OF FIGURES
FIGURE 01. CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031
FIGURE 02. SEGMENTATION OF CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031
FIGURE 03. TOP INVESTMENT POCKETS IN CANCER MONOCLONAL ANTIBODIES MARKET (2022-2031)
FIGURE 04. PORTER FIVE-1
FIGURE 05. PORTER FIVE-2
FIGURE 06. PORTER FIVE-3
FIGURE 07. PORTER FIVE-4
FIGURE 08. PORTER FIVE-5
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALCANCER MONOCLONAL ANTIBODIES MARKET
FIGURE 10. IMPACT OF KEY REGULATION: CANCER MONOCLONAL ANTIBODIES MARKET
FIGURE 11. MARKET SHARE ANALYSIS: CANCER MONOCLONAL ANTIBODIES MARKET
FIGURE 12. PATENT ANALYSIS BY COMPANY
FIGURE 13. PATENT ANALYSIS BY COUNTRY
FIGURE 14. REGULATORY GUIDELINES: CANCER MONOCLONAL ANTIBODIES MARKET
FIGURE 15. VALUE CHAIN ANALYSIS: CANCER MONOCLONAL ANTIBODIES MARKET
FIGURE 16. CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR MURINE, BY COUNTRY 2021-2031(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR CHIMERIC, BY COUNTRY 2021-2031(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR HUMANIZED, BY COUNTRY 2021-2031(%)
FIGURE 20. CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR BLOOD CANCER, BY COUNTRY 2021-2031(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR BREAST CANCER, BY COUNTRY 2021-2031(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR LUNG CANCER, BY COUNTRY 2021-2031(%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
FIGURE 25. CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021(%)
FIGURE 26. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2021-2031(%)
FIGURE 27. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR RESEARCH AND ACADEMIC INSTITUTE/LABORATORIES, BY COUNTRY 2021-2031(%)
FIGURE 28. CANCER MONOCLONAL ANTIBODIES MARKET BY REGION, 2021
FIGURE 29. U.S. CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
FIGURE 30. CANADA CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
FIGURE 31. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
FIGURE 32. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
FIGURE 33. UK CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
FIGURE 34. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
FIGURE 35. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
FIGURE 36. ITALY CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
FIGURE 37. REST OF EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
FIGURE 38. CHINA CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
FIGURE 39. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
FIGURE 40. INDIA CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
FIGURE 41. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
FIGURE 42. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
FIGURE 43. REST OF ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
FIGURE 44. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
FIGURE 45. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
FIGURE 46. UAE CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
FIGURE 47. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
FIGURE 48. REST OF LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
FIGURE 49. TOP WINNING STRATEGIES, BY YEAR
FIGURE 50. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 51. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 52. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 53. COMPETITIVE DASHBOARD
FIGURE 54. COMPETITIVE HEATMAP: CANCER MONOCLONAL ANTIBODIES MARKET
FIGURE 55. TOP PLAYER POSITIONING, 2021

  • Not Sure / Need Reassuring
    • Confirm Content

      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages

      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives

      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices

      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts

      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies

      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses

      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License

      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats

      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery

      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges

      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card

      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer

      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security

      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security

      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE
  • $3456.00 $3110.40
  • $5730.00 $5157.00
  • $9600.00 $8640.00
  • ADD TO BASKET
  • BUY NOW